Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Horizon Pharma PLC (NASDAQ:HZNP)

10.20
Delayed Data
As of May 26
 +0.23 / +2.31%
Today’s Change
9.45
Today|||52-Week Range
23.44
-36.96%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.7B

Company Description

Horizon Pharma Plc engages in the research, development, and market of pharmaceutical products. Its medicines intend to treat arthritis, inflammation, and orphan diseases. It distributes under the following brands: Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos, and Vimovo. The company was founded on December 20, 2011 and is headquartered in Dublin, Ireland.

Contact Information

Horizon Pharma Plc
Connaught House
Dublin Dublin 4
P:(531) 772-2100
Investor Relations:

Employees

Shareholders

Other institutional47.00%
Mutual fund holders38.50%
Individual stakeholders2.09%

Top Executives

Timothy P. WalbertChairman, President & Chief Executive Officer
Paul W. HoelscherChief Financial Officer & Executive Vice President
Jeffrey W. ShermanChief Medical Officer & Executive VP-Research
Tim AyersChief Compliance Officer & Vice President
Brian K. BeelerExecutive Vice President & General Counsel